Plant Name: Corydalis rhizoma
Taxonomic Information:
Plant ID: NPO29701
Plant Latin Name: Corydalis rhizoma
Taxonomy Genus: Corydalis
Taxonomy Family: Papaveraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA1A; HTR7; FFAR1; FFAR4; DRD1; DRD2; HTR2A; HTR1A; | |
| NPSR1; | |
| TDP1; ALOX12; HSD17B10; NOX4; ALOX15; POLB; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| PPARA; | |
| CREBBP; | |
| LMNA; FABP3; FABP5; F3; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | Unclassified; | GO:0004872; receptor activity | 9.000E-10 | 2.178E-06 | ADRA1A, AXL, DRD1, DRD2, F3, FFAR1, FFAR4, FLT3, HTR1A, HTR2A, HTR7, IGF1R, KDR, MET, NPSR1, PPARA |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.234E-08 | 1.560E-05 | CYP1B1, CYP2C19, CYP2C9, CYP2D6, NOX4 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.479E-08 | 1.999E-05 | ADRA1A, AXL, DRD1, DRD2, FFAR1, FFAR4, FLT3, HTR1A, HTR2A, HTR7, IGF1R, KDR, MET, NPSR1 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 3.521E-08 | 2.555E-05 | ADRA1A, ALOX15, DRD2, FFAR4, HTR2A, KDR, NOX4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.054E-08 | 5.188E-05 | CYP2C19, CYP2C9, CYP2D6 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 1.626E-07 | 8.432E-05 | ADRA1A, HTR1A, HTR2A, HTR7 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.706E-07 | 1.228E-04 | ALOX12, ALOX15, CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.407E-07 | 1.996E-04 | CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 7.426E-07 | 2.450E-04 | HTR1A, HTR2A, HTR7 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.399E-06 | 4.172E-04 | ALOX12, CDK1, DRD2, F3, FLT3, HTR1A, HTR2A, IGF1R, KDR, PIM1 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 2.066E-06 | 5.695E-04 | ADRA1A, DRD1, HTR1A, HTR2A, HTR7 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 2.317E-06 | 6.308E-04 | ADRA1A, AURKB, CDK1, HTR2A, NOX4, POLB |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.416E-06 | 6.495E-04 | CYP1B1, CYP2C19, CYP2C9, CYP2D6, NOX4 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.830E-06 | 6.848E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.830E-06 | 6.848E-04 | ALOX12, ALOX15 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 5.077E-06 | 1.140E-03 | DRD1, DRD2, HTR2A |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.917E-06 | 1.301E-03 | CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 7.997E-06 | 1.627E-03 | ALOX12, DRD1, F3, IGF1R, KDR, MET, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 8.482E-06 | 1.694E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 8.482E-06 | 1.694E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 8.973E-06 | 1.714E-03 | HTR1A, HTR2A, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 8.973E-06 | 1.714E-03 | HTR1A, HTR2A, HTR7 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 9.415E-06 | 1.767E-03 | ALOX12, AURKB, AXL, CDK1, FFAR4, IGF1R, KDR, LMNA, PIM1 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.292E-05 | 2.251E-03 | FABP3, FABP5, FFAR4 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.496E-05 | 2.468E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 1.695E-05 | 2.713E-03 | HTR1A, HTR7 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.926E-05 | 3.061E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 1.977E-05 | 3.096E-03 | DRD1, DRD2, HTR2A |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.562E-05 | 3.722E-03 | DRD1, DRD2, HTR2A, KDR, NPSR1 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.622E-05 | 3.781E-03 | CYP2C19, CYP2C9, CYP2D6 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 2.821E-05 | 3.913E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 2.821E-05 | 3.913E-03 | ALOX12, ALOX15 |
| BP | GO:0032502; developmental process | GO:0021885; forebrain cell migration | 2.865E-05 | 3.948E-03 | AXL, DRD1, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0014075; response to amine | 3.679E-05 | 4.797E-03 | CDK1, DRD1, DRD2 |
| BP | GO:0065007; biological regulation | GO:0051282; regulation of sequestering of calcium ion | 3.986E-05 | 5.136E-03 | DRD1, DRD2, HTR2A, NPSR1 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.126E-05 | 5.223E-03 | CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 5.912E-05 | 6.940E-03 | FLT3, KDR |
| BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 7.048E-05 | 8.120E-03 | AURKB, CREBBP, DRD1, DRD2, NOX4, POLB |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 7.280E-05 | 8.343E-03 | CREBBP, DRD2, LMNA, NOX4, PPARA |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 7.874E-05 | 8.884E-03 | DRD1, DRD2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 9.273E-12 | 8.531E-10 | CYP2C9, HTR7, CYP2D6, ALOX15, HTR1A, ALOX12, HTR2A, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.202E-06 | 1.473E-04 | CYP2C9, ALOX15, ALOX12, CYP2C19 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 5.408E-06 | 1.659E-04 | HTR7, HTR1A, HTR2A, DRD1, DRD2, ADRA1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.755E-05 | 2.691E-04 | CREBBP, HTR1A, DRD1, PPARA, DRD2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.299E-05 | 2.672E-04 | CDK1, HTR2A, DRD1, DRD2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.452E-05 | 2.672E-04 | CYP2C9, ALOX15, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 2.117E-04 | 2.049E-03 | HTR7, HTR2A, DRD1, ADRA1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.991E-04 | 2.049E-03 | CYP2C9, CYP2D6, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 3.876E-04 | 2.743E-03 | KDR, DRD2, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.991E-04 | 2.049E-03 | FABP3, FABP5, PPARA |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.353E-04 | 2.049E-03 | CYP2C9, CYP2D6, CYP1B1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.449E-04 | 2.049E-03 | CREBBP, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 5.107E-04 | 3.356E-03 | HTR7, KDR, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.316E-04 | 2.543E-03 | CYP2C9, CYP1B1, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.389E-03 | 8.518E-03 | CREBBP, PIM1, CYP1B1, MET |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; FFAR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| NA: NA | Itching | NA | DRD2; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| NA: NA | Vomiting | NA | DRD2; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ADRA1A; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; CREBBP; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; FFAR1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; HTR1A; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| NA: NA | False perceptions | NA | DRD2; |
| NA: NA | Social phobia | NA | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR1A; |
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; DRD2; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD1; DRD2; HTR2A; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; HTR1A; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; HTR2A; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; HTR2A; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA1A; DRD1; DRD2; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; HTR2A; HTR1A; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; DRD2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; ADRA1A; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | ADRA1A; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | ADRA1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| NA: NA | Hyperaemia | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1A; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR2A; HTR1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA1A; DRD2; HTR2A; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ADRA1A; DRD1; DRD2; HTR1A; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADRA1A; DRD1; HTR1A; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; HTR2A; HTR1A; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| NA: NA | Episode | NA | HTR1A; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; ADRA1A; DRD2; HTR1A; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DRD2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| NA: NA | Addiction | NA | HTR2A; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRA1A; HTR1A; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
